Cardiff, UK – 5th May 2015 – EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay. This new test enables the quantitative determination of PCT in serum samples, EDTA or lithium heparin plasma samples by latex enhanced immunoturbidimetric methodology. Procalcitonin is a marker for bacterial infection and sepsis and has been recognized as an important adjunct marker in the diagnosis of sepsis*.
The new Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay is fast, accurate and convenient. The test provides a precise result, which correlates well with established methodology, within 10 minutes and requires just 20 µL of sample. The reagents may be used on almost any liquid-based chemistry analyzer with open-channel capability. In addition, the reagent kit, calibrator and control sets are all available separately.
Commenting on the cost-effectiveness and convenience of the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay, Al Blanco, Business Unit Director – Central Laboratory at EKF Diagnostics said, “This assay can be performed on a customer’s existing chemistry analyzer with the same collection tube used for analysis of other chemistry tests. Therefore, it will provide optimized lab workflow by eliminating the need to split a sample or have a dedicated off-line workstation. These features will provide any lab with a cost-effective solution for PCT testing.”
*References:
1. Müller B, et al., Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86(1):396-404.
2. Meisner M. Procalcitonin (PCT) – A new, innovative infection parameter. Biochemical and clinical aspects. Thieme; Stuttgart, New York, 2000; ISBN 3-13-105503-0.
3. Christ-Crain M, et al., Procalcitonin in bacterial infections – hype, hope or more or less? Swiss Med Wkly 2005; 135: 451-60.
For more information on Procalcitonin and sepsis testing, the Stanbio Chemistry range or EKF Diagnostics, please visit www.ekfdiagnostics.com.
- ENDS -
This release is also available to view online at:
http://www.ekfdiagnostics.com/news_5_May_2015_EKF_introduces_specific_biomarker_test_for_early_sepsis_identification_161.aspx
Editors’ notes
About EKF Diagnostics - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.
EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
Help employers find you! Check out all the jobs and post your resume.
